New trial suggests that younger women could benefit from annual screening

Breast Cancer Now | February 2019| New trial suggests that younger women could benefit from annual screening

A leading charity has funded research that found evidence that indicates women aged 35-39 at a moderate or high risk of developing breast cancer, could benefit from annual screening.

Professor Gareth Evans, who led the trial funded by Breast Cancer Now, looked at whether screening these women through annual mammograms could pick up tumours earlier. The study found that when tumours were picked up through screening, most were smaller in size, and were less likely to have spread to lymph nodes, compared to women who weren’t screened.

In total 2,899 women aged 35-39 at moderate or high risk of breast cancer due to their family history were offered annual screening across 34 UK centres between 2006 and 2015.

mammography-2416942_640.jpg

In total, 50 breast cancers were detected (in 49 women), of which 35 were invasive tumours. Of the 35 invasive breast cancers, 80% (28/35) were detected by screening when the tumour was 2cm or smaller in size, and only 20% (7/35) had spread to the patients’ lymph nodes.

While the researchers acknowledge that further research to fully understand the risks and benefits of screening this group. However, detecting breast cancer early gives women the best possible chance of survival, and we would like the upcoming review of NHS cancer screening to consider these results and to review services offered to women with a family history of breast cancer.

Breast Cancer Now today called for the upcoming review of NHS cancer screening programmes to include an assessment of family history services across the country, and to set out the health economic evidence required to consider extending screening to women aged 35-39 at moderate or high risk due to their family history (Source: Breast Cancer Now).

Breast Cancer Now Annual screening detects breast cancers earlier for women aged 35-39 with a family history, major UK trial finds

See also:

University of Manchester Annual screening detects breast cancers earlier for women aged 35-39 with a family history

In the news:

BBC News Breast cancer: Scan younger women at risk, charity says

The Recovery Package in lung cancer

VJ Oncology | n.d| The Recovery Package in lung cancer

The Recovery Package sits within the Living With and Beyond Cancer Programme, which is part of the National Cancer Survivorship Initiative, and promotes interventions to form part of an overall support and self-management package for people affected by cancer.

Here, Josie Roberts, RN, of the Rotherham NHS Foundation Trust, Rotherham, UK, discusses the use of the package in lung cancer, and her plans to develop this. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland (Source: Video Journal of Oncology).

Diagnosing lung cancer earlier in Manchester

NHS England | January 2019 |Diagnosing lung cancer earlier in Manchester

NHS England are rolling out the Targeted Lung Health Checks programme as part of their #NHSLongTermPlan to find more cancers quicker. A pilot in Manchester has checked more than 2,500 smokers and ex-smokers.

The on-the spot-scan was received as part of a free health check-it  discovered 46 cases of cancer. Of these, 80% were early stage one and two diagnoses. The pilot quadrupled the early diagnosis rates for lung cancer in Manchester.

The scheme funded by Macmillan Cancer Support and the Manchester Clinical Commissioning Groups through the Macmillan Cancer Improvement Partnership, was rolled-out across the whole of north Manchester, an area which has the highest number of lung cancer deaths among the under-75s in England. It has proved so successful it is now being introduced across the country (Source: NHS England)

Read the full story Diagnosing lung cancer earlier in Manchester

NHS England press release: NHS to rollout lung cancer scanning trucks across the country

In the news:

Guardian NHS to screen for lung cancer in trucks in supermarket car parks

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Technology appraisal guidance [TA557]

NICE | January 2019 | Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Technology appraisal guidance [TA557]

 

Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.

Full details from NICE

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years Technology appraisal guidance [TA554]

NICE | December 2018 | Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years | Technology appraisal guidance [TA554]

 

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years.

 

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

 

See also: NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Technology appraisal guidance [TA555]

NICE | January 2019 |Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Technology appraisal guidance [TA555]

 

Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.

Full details from NICE